Compare Davita Inc (DVA) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Tango Therapeutics Inc. — how do they compare? Davita Inc trades at $180.7 (market cap $11.53B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Davita Inc is far larger — about 3.1× Tango Therapeutics Inc.'s market cap, and Davita Inc is more actively traded (444,368 versus 3,438,781). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Tango Therapeutics Inc. for 0 Days on average.
| DVA | TNGX | |
|---|---|---|
Market Cap | $11.53B | $3.74B |
Volume | 444,368 | 3,438,781 |
Sector | Health | Health |
52-Week High | $240.96 | $32.90 |
52-Week Low | $103.87 | $7.50 |
Typical Hold Time | 114 Days | 0 Days |
Enterprise Value | $24.25B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $182.08, up 0.17% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026), revenue growth from $11.6B to $13.6B (2022-2025), and attractive valuation at P/E 15.43. Recent partnership expansion with Humana for value-based kidney care and institutional buying by BlackRock ($547.5M) support positive momentum. Operating cash flow remains robust at $1.89B (2025), though net cash flow turned negative due to debt repayments.
Outlook: DVA offers upside to consensus target ($235.67) with 29% potential, backed by earnings growth and strategic partnerships. Risks include high debt (debt-to-asset 65.55%), regulatory pressures, and margin volatility. Analyst consensus leans Hold (52.17%) amid balanced growth prospects and financial leverage concerns.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
